Global Intravenous Immunoglobulin Market [By Application (Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Hypogammaglobulinemia, Congenital AIDS, Immunodeficiency diseases, Multifocal motor neuropathy, Myasthenia Gravis, Chronic Lymphocytic Leukemia, Kawasaki disease, Guillain-Barre syndrome, and Idiopathic Thrombocytopenic Purpura (ITP)); and by Regions]: Market size & Forecast, 2018 – 2026

Final Report will cover Impact of Covid-19 And Russia-Ukraine War

The Global Intravenous Immunoglobulin Market Size is anticipated to reach over USD 16,882.15 Million by 2026, according to a new research published by Polaris Market Research

Immunoglobulins (IGs) are glycoproteins that are formed in the blood plasma in response to the antigens (Ag), which are considered as a foreign material to the host system. IGs are highly composite objects and precise in their nature. They are achieved from blood by fractionation procedure and filtered fo non-therapeutic as well as therapeutic applications. In therapeutics, they are administered intravenously for the treatment of several immunodeficiency.

The global Intravenous Immunoglobulin Market majorly is driven by rising elderly population, increasing occurrence of immunodeficiency disorders, growing implementation of IVIG procedures and increasing usage of off-label indications. Increasing number of patients with immunodeficiency disease is the primary reason for the expansion of IVIG procedures. According to the World Health Organization (WHO), there are approximately 50 diverse Primary Immune Deficiency (PID) such as X-lined hypo-gamma-globulinemia, specific antibody deficiency and others. Moreover, according to the U.S. National Library of Medicine and National Institute of Health, around 6 million patients are suffering from PID globally. Rising occurrences of these immune diseases is anticipated to bolster the demand for intravenous immunoglobulin treatments during the forecast period. The demand for IVIG treatments for the primary and acquired immunodeficiency disorder is growing as it is the only available as well as most effective treatment option. Moreover, inactive lifestyle behaviors, including intake of saturated fats, sugars and salts, less physical actions, and high alcohol intake have led to the surge in the occurrence of such diseases. Increasing occurrence of such lifestyle related disease including antibody deficiency disorders and obesity are the factors anticipated to drive the global intravenous immunoglobulin market growth.

The global Intravenous Immunoglobulin Market is segmented on the basis of Application and geography. On the basis of application, the global Intravenous Immunoglobulin Market is categorized into Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Hypogammaglobulinemia, Congenital AIDS, Immunodeficiency diseases, Multifocal motor neuropathy, Myasthenia Gravis, Chronic Lymphocytic Leukemia, Kawasaki disease, Guillain-Barre syndrome, and Idiopathic Thrombocytopenic Purpura (ITP). In 2017, Hypogammaglobulinemia is estimated to dominate the application segment. The dominancy is attributed to the growing global occurrences of primary immunodeficiency diseases (PID). It is the most common chronic immune defect in patients with lymphoproliferative disorders (LPDs). According to the Centers for Disease Control and Prevention (CDC) in 2012, the global occurrence rate of hypogammaglobulinemia was around 2 per 100,000 populations moreover, the number of people suffering this type of disease are estimated to increase during the forecast period. Growing occurrence of immunodeficiency disorders associated with the high implementation of IVIG therapies is expected to drive the segment growth significantly.

Some major key players in global Intravenous Immunoglobulin Market include Baxter International Inc., CSL Ltd., Grifols S.A, Octapharma AG, Kedrion Biopharma Inc., LFB group, Biotest AG, China Biologics Products, Inc., BDI Pharma Inc., and Bayer Healthcare among others.

Table of Contents
1. Overview and Scope
1.1. Research goal & scope
1.2. Research assumptions
1.3. Research Methodology
1.3.1. Primary data sources
1.3.2. Secondary data sources
1.4. Key take-aways
1.5. Stakeholders
2. Executive Summary
2.1. Market Definition
2.2. Market Segmentation
3. Intravenous Immunoglobulin Market Insights
3.1. Intravenous Immunoglobulin – Industry snapshot
3.2. Intravenous Immunoglobulin - Ecosystem analysis
3.3. Intravenous Immunoglobulin Market dynamics
3.3.1. Intravenous Immunoglobulin – Market Forces
3.3.1.1. Intravenous Immunoglobulin Market driver analysis
3.3.1.2. Intravenous Immunoglobulin Market restraint/challenges analysis
3.3.1.3. Intravenous Immunoglobulin Market opportunity analysis
3.4. Industry analysis - Porter's five force
3.4.1. Bargaining power of supplier
3.4.2. Bargaining power of buyer
3.4.3. Threat of substitute
3.4.4. Threat of new entrant
3.4.5. Degree of competition
3.5. Intravenous Immunoglobulin Market PEST analysis, 2017
3.5.1. Intravenous Immunoglobulin Industry trends
3.5.2. Competitive Ranking Analysis
4. Intravenous Immunoglobulin Market Size and Forecast by Application
4.1. Key findings
4.2. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
4.2.1. Global market estimates and forecasts, 2017 - 2026
4.3. Hypogammaglobulinemia
4.3.1. Global market estimates and forecasts, 2017 - 2026
4.4. Congenital AIDS
4.4.1. Global market estimates and forecasts, 2017 - 2026
4.5. Immunodeficiency diseases
4.5.1. Global market estimates and forecasts, 2017 - 2026
4.6. Multifocal motor neuropathy
4.6.1. Global market estimates and forecasts, 2017 - 2026
4.7. Myasthenia Gravis
4.7.1. Global market estimates and forecasts, 2017 - 2026
4.8. Chronic Lymphocytic Leukemia
4.8.1. Global market estimates and forecasts, 2017 - 2026
4.9. Kawasaki disease
4.9.1. Global market estimates and forecasts, 2017 - 2026
4.10. Guillain-Barre syndrome
4.10.1. Global market estimates and forecasts, 2017 - 2026
4.11. Idiopathic Thrombocytopenic Purpura (ITP)
4.11.1. Global market estimates and forecasts, 2017 - 2026
5. Intravenous Immunoglobulin Market Size and Forecast by Regions
5.1. Key findings
5.2. North America
5.2.1. Intravenous Immunoglobulin Market by Application, 2017 - 2026
5.2.2. U.S.
5.2.2.1. Intravenous Immunoglobulin Market by Application, 2017 - 2026
5.2.3. Canada
5.2.3.1. Intravenous Immunoglobulin Market by Application, 2017 - 2026
5.3. Europe
5.3.1. Intravenous Immunoglobulin Market by Application, 2017 - 2026
5.3.2. Germany
5.3.2.1. Intravenous Immunoglobulin Market by Application, 2017 - 2026
5.3.3. UK
5.3.3.1. Intravenous Immunoglobulin Market by Application, 2017 - 2026
5.3.4. France
5.3.4.1. Intravenous Immunoglobulin Market by Application, 2017 - 2026
5.3.5. Italy
5.3.5.1. Intravenous Immunoglobulin Market by Application, 2017 - 2026
5.4. Asia Pacific
5.4.1. Intravenous Immunoglobulin Market by Application, 2017 - 2026
5.4.2. China
5.4.2.1. Intravenous Immunoglobulin Market by Application, 2017 - 2026
5.4.3. India
5.4.3.1. Intravenous Immunoglobulin Market by Application, 2017 - 2026
5.4.4. Japan
5.4.4.1. Intravenous Immunoglobulin Market by Application, 2017 - 2026
5.4.5. Australia
5.4.5.1. Intravenous Immunoglobulin Market by Application, 2017 - 2026
5.5. Latin America
5.5.1. Intravenous Immunoglobulin Market by Application, 2017 - 2026
5.5.2. Brazil
5.5.2.1. Intravenous Immunoglobulin Market by Application, 2017 - 2026
5.5.3. Mexico
5.5.3.1. Intravenous Immunoglobulin Market by Application, 2017 - 2026
5.6. Middle East & Africa
5.6.1. Intravenous Immunoglobulin Market by Application, 2017 - 2026
6. Company Profiles
6.1. Baxter International Inc.
6.1.1. Overview
6.1.2. Financials
6.1.3. Product Benchmarking
6.1.4. Recent Developments
6.2. CSL Ltd.
6.2.1. Overview
6.2.2. Financials
6.2.3. Product Benchmarking
6.2.4. Recent Developments
6.3. Grifols S.A
6.3.1. Overview
6.3.2. Financials
6.3.3. Product Benchmarking
6.3.4. Recent Developments
6.4. Octapharma AG
6.4.1. Overview
6.4.2. Financials
6.4.3. Product Benchmarking
6.4.4. Recent Developments
6.5. Kedrion Biopharma Inc.
6.5.1. Overview
6.5.2. Financials
6.5.3. Product Benchmarking
6.5.4. Recent Developments
6.6. LFB group
6.6.1. Overview
6.6.2. Financials
6.6.3. Product Benchmarking
6.6.4. Recent Developments
6.7. Biotest AG
6.7.1. Overview
6.7.2. Financials
6.7.3. Product Benchmarking
6.8. China Biologics Products, Inc.
6.8.1. Overview
6.8.2. Financials
6.8.3. Product Benchmarking
6.8.4. Recent Developments
6.9. BDI Pharma Inc.
6.9.1. Overview
6.9.2. Financials
6.9.3. Product Benchmarking
6.9.4. Recent Developments
6.10. Bayer Healthcare
6.10.1. Overview
6.10.2. Financials
6.10.3. Product Benchmarking
6.10.4. Recent Developments

List of Figures

50% OFF

Report Price

Contact Us

Quick Links

Payment